Zhen Huang

Dr. Zhen Huang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
ZHZhen Huang
Zhen Huang
CMChongde Mo
Chongde Mo
LLLihui Li
Lihui Li
QHQiyan Hou
Qiyan Hou
YPYinhua Pan
Yinhua Pan
JYJianrong Yang
Jianrong Yang
Background: Breast cancer (BC) ranks as one of the most prevalent malignancies among women globally. This study aimed to explore the involvement of neutrophil extracellular traps (NETs)-related genes (NETRGs) in BC pathogenesis, highlighting the critical role of NETs. Methods: Differentially expressed NETRGs (DE-NETRGs) were identified by intersecting BC vs. control differentially expressed genes (DEGs) with the NETRG gene set from The Cancer Genome Atlas breast invasive carcinoma (TCGA-BRCA) and GSE42568 datasets. Functional analysis elucidated their biological roles. Prognostic biomarkers were selected using least absolute shrinkage and selection operator (LASSO) and Cox regression, generating a predictive model, of which its prognostic predictive ability was evaluated through the Kaplan-Meier (KM) survival curve and receiver operating characteristic (ROC) curve, and verified it in the test set and the validation set. Subsequently, the clinicopathological features were incorporated into the risk model for Cox independent prognostic analysis, and a nomogram was constructed to verify the predictive performance of the model. Finally, the mechanism of action of the biomarkers in BC was explored through immune infiltration, immunotherapy, and drug sensitivity. The biomarker expression validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results: Functional analysis revealed 37 DE-NETRGs associated with leukocyte migration and the Interleukin (IL)-17 signaling pathway. Four biomarkers [F2RL2, AZU1, IL33, neutrophil elastase (ELANE)] were used to construct the prognostic model and it was validated by the test set and the validation set. The KM curve showed significant differences in prognosis between the high- and low-risk group, while the ROC curve showed that the model had good predictive performance. Radiation, age, tumor stage, pathologic N, and risk scores were identified as independent prognostic factors. Subgroups based on risk scores exhibited distinct immune cell infiltration patterns, with the risk score positively correlated with M0 macrophages and resting mast cells. The high-risk group demonstrated lower Tumor Immune Dysfunction and Exclusion (TIDE) scores. Drug sensitivity varied between risk subgroups, and qRT-PCR confirmed the expression of ELANE and IL33. Conclusions: This study has reported four biomarkers related to BC prognosis, namely F2RL2, AZU1, IL33, and ELANE. Our study has offered new potential biomarkers for prognosis and has identified therapeutic targets for the treatment and prognosis prediction in BC patients.

1 August 2026 in Molecular Carcinogenesis
Verified
Journal Article
Open access
ZHZhen Huang
Zhen Huang
ZWZhe Wu
Zhe Wu
GZGuiyue Zhu
Guiyue Zhu
FQFangyu Qiu
Fangyu Qiu
LLLihui Li
Lihui Li
YTYuntian Tang
Yuntian Tang
Neutrophil extracellular traps (NETs) play crucial roles in cancer progression, but their regulatory mechanisms in breast cancer remain poorly understood. We developed a NETs‐related prognostic risk model using TCGA breast cancer data and identified key biomarkers through bioinformatics analysis. AZU1 expression was validated in clinical samples using qRT‐PCR and immunohistochemistry. In vitro experiments investigated AZU1's effects on neutrophil activation and NET formation using recombinant protein treatment, co‐culture assays, and flow cytometry. Mechanistic studies employed phospholipase C (PLC) inhibition and PAD4 knockdown approaches. An orthotopic mouse model validated in vivo findings. Four NETs‐related genes (F2RL2, AZU1, IL33, ELANE) constituted a robust prognostic model with good predictive performance. AZU1 showed significant upregulation in breast cancer tissues and correlated with advanced tumor stages. AZU1 overexpression in breast cancer cells enhanced neutrophil recruitment and NET formation through PLC signaling activation. Recombinant AZU1 dose‐dependently activated neutrophils, promoted NET formation, and enhanced cancer cell invasion via epithelial‐mesenchymal transition induction. PLC inhibition and PAD4 knockdown effectively blocked AZU1‐induced neutrophil activation. In vivo experiments confirmed that AZU1 overexpression accelerated tumor growth and metastasis, while PAD4 inhibition reversed these effects. AZU1 promotes breast cancer progression through PAD4‐dependent NET formation, representing a potential therapeutic target for breast cancer treatment.

25 April 2025 in Medicine
Verified
Journal Article
Open access
JWJing Mm Wei
Jing Mm Wei
CMChong-De Mm Mo
Chong-De Mm Mo
GZGui-Yue Mm Zhu
Gui-Yue Mm Zhu
FQFang-Yu Mm Qiu
Fang-Yu Mm Qiu
SQSheng-Peng Mm Qin
Sheng-Peng Mm Qin
YJYang jianrong
Yang jianrong
Breast cancer (BC) has the second highest incidence rate among women worldwide. Although there are various treatment methods, the prognosis is poor once metastasis occurs. However, the extent to which pathogens of infectious diseases influence the risk of BC remains unclear. The goal of this study is to determine if these pathogens are causally related to BC development. A Mendelian randomization (MR) analysis is used to assess the causal relationship between infectious pathogen antibodies and the risk of BC, as well as their potential intermediary factors. Two-sample MR analysis using inverse variance weighting (IVW) is conducted to determine the causal relationship between infectious pathogen antibodies and the risk of BC. Additionally, the mediating role of 1400 metabolites between infectious pathogen antibodies and the risk of BC is analyzed. There were 5 infectious pathogen antibodies and 86 metabolites associated with BC (P < .05). There were 14 metabolites that mediated the pathway between infectious pathogen antibodies and BC. X-07765 levels showed a significant negative mediating effect on the relationship between Anti-human herpes virus 6 IgG seropositivity and BC (beta = −0.0025, 95% CI [−0.0046, −0.0003], P = .0236), accounting for 14.8% of the effect (95% CI: 27.7–1.99). This study provides a thorough evaluation of the causal relationships among infectious pathogen antibodies, plasma metabolites, and BC. Our research has identified 5 infectious pathogen antibodies that exhibit a causal relationship with BC, mediated through 86 distinct metabolites.